Method of treating and reducing the risk of acute myelogenous leukemia

Abstract

The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AMLI-ETO acetylation. The present invention further provides methods of using these treatments.

1 .- 17 . (canceled) 
     
     
         18 . A method of treating or reducing risk for acute myelogenous leukemia comprising administering to a subject one or more AML1-ETO acetylation inhibitors. 
     
     
         19 . The method of  claim 18  wherein the one or more AML1-ETO acetylation inhibitors are identified by:
 determining transcription levels of one or more targets of AML1-ETO transcriptional activation contacted to a test agent; and 
 identifying the test agent as treating or reducing risk for acute myelogenous leukemia if the transcription levels are reduced relative to transcription levels in comparable conditions lacking the test agent. 
 
     
     
         20 . The method of  claim 19 , wherein one or more targets of AML1-ETO transcriptional activation comprises Id1, p21 or Egr1. 
     
     
         21 . The method of  claim 18 , wherein administering to a subject one or more AML1-ETO acetylation inhibitors characterized in that transcription levels of one or more targets of AML1-ETO transcriptional activation are lower in the presence of the one or more AML1-ETO acetylation inhibitors as compared with in its absence. 
     
     
         22 . The method of  claim 18 , wherein the one or more AML1-ETO acetylation inhibitors is or was identified or characterized by a method comprising steps of:
 (a) providing a system in which AML1-ETO acetylation level is determinable;   (b) contacting the system with a test agent;   (c) determining AML1-ETO acetylation level when the test agent is present;   (d) comparing the determined AML1-ETO acetylation level with a reference AML1-ETO acetylation level so that any difference between the reference level and the determined level is detected; and   (e) identifying or characterizing the test agent's usefulness in treating or reducing risk for acute myelogenous leukemia based on the detected difference.